An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis - PubMed (original) (raw)
. 2010 Jul 9;329(5988):229-32.
doi: 10.1126/science.1190354. Epub 2010 Jun 3.
Michael Ewing, Pamela Hale, Christine Dippold, Caroline Beckett, Carolyn Kemp, Nicholas Maurice, Amitava Mukherjee, Christina Goldbach, Simon Watkins, George Michalopoulos, David H Perlmutter
Affiliations
- PMID: 20522742
- DOI: 10.1126/science.1190354
An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis
Tunda Hidvegi et al. Science. 2010.
Abstract
In the classical form of alpha1-antitrypsin (AT) deficiency, a point mutation in AT alters the folding of a liver-derived secretory glycoprotein and renders it aggregation-prone. In addition to decreased serum concentrations of AT, the disorder is characterized by accumulation of the mutant alpha1-antitrypsin Z (ATZ) variant inside cells, causing hepatic fibrosis and/or carcinogenesis by a gain-of-toxic function mechanism. The proteasomal and autophagic pathways are known to mediate degradation of ATZ. Here we show that the autophagy-enhancing drug carbamazepine (CBZ) decreased the hepatic load of ATZ and hepatic fibrosis in a mouse model of AT deficiency-associated liver disease. These results provide a basis for testing CBZ, which has an extensive clinical safety profile, in patients with AT deficiency and also provide a proof of principle for therapeutic use of autophagy enhancers.
Comment in
- Medicine. Clearing conformational disease.
Sifers RN. Sifers RN. Science. 2010 Jul 9;329(5988):154-5. doi: 10.1126/science.1192681. Science. 2010. PMID: 20616258 No abstract available. - Genetic diseases: new tricks for known drugs.
Harrison C. Harrison C. Nat Rev Drug Discov. 2010 Aug;9(8):595. doi: 10.1038/nrd3232. Nat Rev Drug Discov. 2010. PMID: 20671762 No abstract available. - Drug enhanced autophagy to fight mutant protein overload.
Mehrpour M, Codogno P. Mehrpour M, et al. J Hepatol. 2011 May;54(5):1066-8. doi: 10.1016/j.jhep.2010.11.032. Epub 2010 Dec 16. J Hepatol. 2011. PMID: 21167888 No abstract available. - Controlling autophagy: a new concept for clearing liver disease.
Tacke F, Trautwein C. Tacke F, et al. Hepatology. 2011 Jan;53(1):356-8. doi: 10.1002/hep.24090. Hepatology. 2011. PMID: 21254183 No abstract available.
Similar articles
- Medicine. Clearing conformational disease.
Sifers RN. Sifers RN. Science. 2010 Jul 9;329(5988):154-5. doi: 10.1126/science.1192681. Science. 2010. PMID: 20616258 No abstract available. - Alpha1-antitrypsin deficiency and autophagy.
Marciniak SJ, Lomas DA. Marciniak SJ, et al. N Engl J Med. 2010 Nov 4;363(19):1863-4. doi: 10.1056/NEJMcibr1008007. N Engl J Med. 2010. PMID: 21047232 No abstract available. - Targeting intracellular degradation pathways for treatment of liver disease caused by α1-antitrypsin deficiency.
Wang Y, Perlmutter DH. Wang Y, et al. Pediatr Res. 2014 Jan;75(1-2):133-9. doi: 10.1038/pr.2013.190. Epub 2013 Nov 13. Pediatr Res. 2014. PMID: 24226634 Free PMC article. Review. - Fluphenazine reduces proteotoxicity in C. elegans and mammalian models of alpha-1-antitrypsin deficiency.
Li J, Pak SC, O'Reilly LP, Benson JA, Wang Y, Hidvegi T, Hale P, Dippold C, Ewing M, Silverman GA, Perlmutter DH. Li J, et al. PLoS One. 2014 Jan 31;9(1):e87260. doi: 10.1371/journal.pone.0087260. eCollection 2014. PLoS One. 2014. PMID: 24498058 Free PMC article.
Cited by
- USF2 and TFEB compete in regulating lysosomal and autophagy genes.
Kim J, Yu YS, Choi Y, Lee DH, Han S, Kwon J, Noda T, Ikawa M, Kim D, Kim H, Ballabio A, Kim KI, Baek SH. Kim J, et al. Nat Commun. 2024 Sep 27;15(1):8334. doi: 10.1038/s41467-024-52600-2. Nat Commun. 2024. PMID: 39333072 Free PMC article. - ER-to-lysosome-associated degradation acts as failsafe mechanism upon ERAD dysfunction.
Fasana E, Fregno I, Galli C, Soldà T, Molinari M. Fasana E, et al. EMBO Rep. 2024 Jun;25(6):2773-2785. doi: 10.1038/s44319-024-00165-y. Epub 2024 May 21. EMBO Rep. 2024. PMID: 38773321 Free PMC article. - Tracing genetic diversity captures the molecular basis of misfolding disease.
Zhao P, Wang C, Sun S, Wang X, Balch WE. Zhao P, et al. Nat Commun. 2024 Apr 18;15(1):3333. doi: 10.1038/s41467-024-47520-0. Nat Commun. 2024. PMID: 38637533 Free PMC article. - Variants in autophagy genes MTMR12 and FAM134A are putative modifiers of the hepatic phenotype in α1-antitrypsin deficiency.
Tafaleng EN, Li J, Wang Y, Hidvegi T, Soto-Gutierrez A, Locke AE, Nicholas TJ, Wang YC, Pak S, Cho MH, Silverman EK, Silverman GA, Jin SC, Fox IJ, Perlmutter DH. Tafaleng EN, et al. Hepatology. 2024 Oct 1;80(4):859-871. doi: 10.1097/HEP.0000000000000865. Epub 2024 Apr 1. Hepatology. 2024. PMID: 38557779 Free PMC article. - A Collagen10a1 mutation disrupts cell polarity in a medaka model for metaphyseal chondrodysplasia type Schmid.
Tan WH, Rücklin M, Larionova D, Ngoc TB, Joan van Heuven B, Marone F, Matsudaira P, Winkler C. Tan WH, et al. iScience. 2024 Mar 4;27(4):109405. doi: 10.1016/j.isci.2024.109405. eCollection 2024 Apr 19. iScience. 2024. PMID: 38510140 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- HL037784/HL/NHLBI NIH HHS/United States
- R01 DK084512/DK/NIDDK NIH HHS/United States
- RR022241/RR/NCRR NIH HHS/United States
- R01 DK076918/DK/NIDDK NIH HHS/United States
- DK076918/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases